These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 6607323)

  • 41. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy.
    Clark RH; Dimitrov NV; Axelson JA; Charamella LJ
    J Biol Response Mod; 1984 Dec; 3(6):613-9. PubMed ID: 6512561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients.
    Mantovani L; Guglielmi C; Martelli M; Chierichini A; Deriu L; Sertoli MR; Ardizzoni A; Mandelli F
    Haematologica; 1989; 74(6):571-5. PubMed ID: 2628239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
    J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of human leukocyte interferon in patients with advanced cancer.
    Horning SJ; Levine JF; Meyer M; Merigan TC; Rosenberg SA
    J Biol Response Mod; 1983; 2(1):47-56. PubMed ID: 6196450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancement of a human antibody response in vitro mediated by interaction of interferon-alpha with T lymphocytes.
    Evans SS; Ozer H
    J Immunol; 1987 Apr; 138(8):2451-6. PubMed ID: 2951440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma].
    Furue H
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1625-9. PubMed ID: 3896154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+].
    Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Schwarzenberg L; Machover D; Ribaud P; de Vassal F
    Biomed Pharmacother; 1982 Mar; 36(2):112-6. PubMed ID: 7126777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Ely S; Furman RR; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Cesano A; Goldenberg DM
    J Clin Oncol; 2003 Aug; 21(16):3051-9. PubMed ID: 12837807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.
    Saks S; Rosenblum M
    Immunol Ser; 1992; 56():567-87. PubMed ID: 1550875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha-interferon induces enhanced expression of HLA-ABC antigens and beta-2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells.
    Nissen MH; Larsen JK; Plesner T; Olesen BK; Ernst P
    Clin Exp Immunol; 1987 Sep; 69(3):632-8. PubMed ID: 2959413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
    Mazzaro C; Franzin F; Tulissi P; Pussini E; Crovatto M; Carniello GS; Efremov DG; Burrone O; Santini G; Pozzato G
    Cancer; 1996 Jun; 77(12):2604-13. PubMed ID: 8640712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase.
    Case DC; Sonneborn HL; Paul SD; Hiebel J; Boyd MA; Shepp MA; Dorsk BM; Bonnem E
    Cancer Treat Rep; 1986 Nov; 70(11):1251-4. PubMed ID: 3768870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.